Range Low Price High Price Comment
30 days $5.11 $7.41 Tuesday, 30th Apr 2024 EDIT stock ended at $5.21. This is 2.98% less than the trading day before Monday, 29th Apr 2024. During the day the stock fluctuated 3.08% from a day low at $5.20 to a day high of $5.36.
90 days $5.11 $11.58
52 weeks $5.11 $11.90

Historical Editas Medicine, Inc prices

Date Open High Low Close Volume
Apr 30, 2024 $5.33 $5.36 $5.20 $5.21 1 221 219
Apr 29, 2024 $5.38 $5.54 $5.31 $5.37 1 234 275
Apr 26, 2024 $5.25 $5.40 $5.13 $5.32 1 334 238
Apr 25, 2024 $5.27 $5.27 $5.11 $5.22 1 502 421
Apr 24, 2024 $5.51 $5.57 $5.28 $5.35 1 497 929
Apr 23, 2024 $5.60 $5.92 $5.46 $5.46 1 620 744
Apr 22, 2024 $5.59 $5.79 $5.39 $5.60 1 685 469
Apr 19, 2024 $5.52 $5.68 $5.29 $5.49 2 226 987
Apr 18, 2024 $5.60 $5.68 $5.51 $5.55 1 712 452
Apr 17, 2024 $5.89 $5.90 $5.60 $5.61 1 905 196
Apr 16, 2024 $5.98 $6.03 $5.85 $5.85 1 295 721
Apr 15, 2024 $6.25 $6.29 $5.98 $6.08 1 710 630
Apr 12, 2024 $6.53 $6.53 $6.13 $6.21 1 989 660
Apr 11, 2024 $6.65 $6.77 $6.44 $6.58 1 473 176
Apr 10, 2024 $6.80 $6.80 $6.54 $6.63 2 098 077
Apr 09, 2024 $6.74 $7.03 $6.67 $7.01 1 567 229
Apr 08, 2024 $6.74 $6.87 $6.68 $6.72 977 412
Apr 05, 2024 $6.77 $6.85 $6.65 $6.72 1 253 970
Apr 04, 2024 $7.00 $7.08 $6.77 $6.81 1 830 381
Apr 03, 2024 $6.82 $7.02 $6.65 $6.86 1 767 062
Apr 02, 2024 $7.12 $7.13 $6.86 $6.87 2 151 476
Apr 01, 2024 $7.41 $7.41 $7.15 $7.28 1 246 510
Mar 28, 2024 $7.46 $7.52 $7.37 $7.42 1 490 429
Mar 27, 2024 $7.31 $7.53 $7.19 $7.44 1 242 373
Mar 26, 2024 $7.46 $7.59 $7.20 $7.22 1 583 430
Click to get the best stock tips daily for free!

About Editas Medicine, Inc

Editas Medicine Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic... EDIT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT